- Home
- FMST vs MNPR Comparison
FMST vs MNPR Comparison
Compare FMST & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- MNPR
- Stock Information
- Founded
- FMST 2005
- MNPR 2014
- Country
- FMST Canada
- MNPR United States
- Employees
- FMST N/A
- MNPR N/A
- Industry
- FMST Other Metals and Minerals
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- MNPR Health Care
- Exchange
- FMST Nasdaq
- MNPR Nasdaq
- Market Cap
- FMST 15.8M
- MNPR 16.3M
- IPO Year
- FMST N/A
- MNPR 2019
- Fundamental
- Price
- FMST $2.00
- MNPR $18.10
- Analyst Decision
- FMST
- MNPR Strong Buy
- Analyst Count
- FMST 0
- MNPR 3
- Target Price
- FMST N/A
- MNPR $27.33
- AVG Volume (30 Days)
- FMST 13.3K
- MNPR 1.5M
- Earning Date
- FMST 01-01-0001
- MNPR 11-08-2024
- Dividend Yield
- FMST N/A
- MNPR N/A
- EPS Growth
- FMST N/A
- MNPR N/A
- EPS
- FMST N/A
- MNPR N/A
- Revenue
- FMST N/A
- MNPR N/A
- Revenue This Year
- FMST N/A
- MNPR N/A
- Revenue Next Year
- FMST N/A
- MNPR N/A
- P/E Ratio
- FMST N/A
- MNPR N/A
- Revenue Growth
- FMST N/A
- MNPR N/A
- 52 Week Low
- FMST $1.94
- MNPR $1.37
- 52 Week High
- FMST $4.25
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- FMST 33.44
- MNPR 59.78
- Support Level
- FMST $1.94
- MNPR $16.26
- Resistance Level
- FMST $2.19
- MNPR $19.70
- Average True Range (ATR)
- FMST 0.19
- MNPR 2.07
- MACD
- FMST -0.01
- MNPR -0.08
- Stochastic Oscillator
- FMST 8.43
- MNPR 72.29
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.